RECEIVED **CENTRAL FAX CENTER**

FEB. 7. 2005 3:06PM AVENTIS US PAT DEPT

NO. 2017 P. 1/7

FEB 0 7 2005

			U.	S. Palent and	emeherT.	rk Office:	PTO/SE/21 (09-04) Clinough 07/31/2006, OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no parsons			s are required to respond to a Application Number	collection of	Clion of information unless it displays a valid OMB.compl		
TRANSMITTAL FORM			Filing Date		10/622,817		
			First Named Inventor		July 18, 2003 Olga CORTI et al.		
FORW			Art Unit		1653		
		Examiner Name					
(to be used for all correspondence after initial filing)		Attorney Docket Number	. 	CARLSON, Karen C.			
Total Number of Pages in This Submission 7				FHAV	FRAV2002/0020 US NP		
ENCLOSURES (Check all that apply)							
Fee Attached Amendment/Reply After Final Aftidavits/declaration(s) Extension of Time Request Express Abandonment Request		rawing(s) icensing-related Papers etition etition to Convert to a rovisional Application ower of Attorney, Revocation change of Correspondence Address erminal Disclaimer equest for Refund D, Number of CD(s)			Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 Landscape Table on CD Remarks 1. Transmittal Letter (6 pages)							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name AVENTIS PHARMACEUTICALS INC.							
Signature L. C.							
Printed name Jeel B. German							
Dale	February 07, 2005 Reg. No. 48,676						
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in arrenvelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date hown below: OSPTO-PAX NO. 703-872-9306 ; Total No. of Pages Transmitted:7							
Signature Typed or printed a	name Jorias Rierre, Sr.					Date	February 07, 2005

This collection of information is required by 33 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Comfidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the tridividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

三二三年第二五

In re Application of CORTI, et al.

Examiner:

CARLSON, Karen C.

RECEIVED
CENTRAL FAX CENTER

Art Unit:

1653

FEB 0 7 2005

Filed:

Application No.: 10/622,817

July 18, 2003

TELEFAX CERTIFICATE

Title:

METHOD FOR DETERMINING THE

ABILITY OF A COMPOUND TO MODIFY THE INTERACTION BETWEEN PARKIN AND THE P38

I hereby certify that this correspondence is being transmitted yie facsimile to the Commissioner for Patients, Alexandria, VA 22313, on

February 7, 2005

INSTITUTE ST

AMENDMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs,

In response to the Office Action of January 11, 2005, the Applicants amend the abovereferenced application as follows:

Amendments to the claims begin on page 2.

Remarks begin on page 6.